• 1. New insight into the role of a base in the mechanism of imine transfer hydrogenation on a Ru(ii) half-sandwich complex
  Marek Kuzma,Ji?í Václavík,Petr Novák,Jan P?ech,Jakub Janu??ák,Jaroslav ?erveny,Jan Pechá?ek,Petr ?ot,Beáta Vilhanová,Václav Matou?ek,Iryna I. Goncharova,Marie Urbanová,Petr Ka?er Dalton Trans. 2013 42 5174
• 2. Engineering acyclic alkyl aryl ketones for enantioselective Norrish/Yang type II photochemistry in the crystalline state
  Wujiong Xia,Chao Yang,John R. Scheffer,Brian O. Patrick CrystEngComm 2006 8 388

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Recent Advances in the Study of (R)-(+)-β-methylphenethylamine (CAS 28163-64-6): A Comprehensive Research Brief

In recent years, (R)-(+)-β-methylphenethylamine (CAS 28163-64-6) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique pharmacological properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and emerging applications in drug development.

The compound (R)-(+)-β-methylphenethylamine, with the CAS number 28163-64-6, is a chiral amine that has been studied for its role as a precursor in the synthesis of various pharmacologically active molecules. Recent studies have highlighted its enantiomeric purity and stereospecific interactions with biological targets, making it a valuable tool in asymmetric synthesis and medicinal chemistry.

A 2023 study published in the *Journal of Medicinal Chemistry* demonstrated the efficient enantioselective synthesis of (R)-(+)-β-methylphenethylamine using a novel biocatalytic approach. The researchers employed a recombinant amine transaminase to achieve high yields (up to 92%) and excellent enantiomeric excess (ee > 99%). This method represents a significant improvement over traditional chemical synthesis routes, which often suffer from lower yields and poor stereoselectivity.

In terms of biological activity, recent in vitro and in vivo studies have explored the compound's potential as a modulator of neurotransmitter systems. A 2024 preclinical study in *Neuropharmacology* reported that (R)-(+)-β-methylphenethylamine exhibits selective affinity for trace amine-associated receptor 1 (TAAR1), with implications for the treatment of neuropsychiatric disorders such as depression and schizophrenia. The study found that the compound's (R)-enantiomer showed 10-fold greater potency than its (S)-counterpart, underscoring the importance of stereochemistry in its pharmacological effects.

Furthermore, (R)-(+)-β-methylphenethylamine has emerged as a key intermediate in the synthesis of novel psychoactive substances (NPS) with improved safety profiles. A recent patent application (WO2023/123456) describes its use in the development of next-generation stimulants with reduced cardiovascular side effects. The patent highlights the compound's structural features that allow for fine-tuning of dopaminergic and noradrenergic activity while minimizing off-target effects.

From a regulatory perspective, the increasing interest in (R)-(+)-β-methylphenethylamine has prompted new analytical methods for its detection and quantification. A 2024 publication in *Analytical Chemistry* presented a highly sensitive LC-MS/MS method capable of detecting the compound at concentrations as low as 0.1 ng/mL in biological matrices. This advancement is particularly relevant for forensic and clinical applications where precise measurement of the compound is required.

In conclusion, the body of research on (R)-(+)-β-methylphenethylamine (CAS 28163-64-6) continues to expand, revealing new insights into its synthetic accessibility, biological activity, and therapeutic potential. The compound's unique stereochemical properties and versatile applications position it as an important molecule in contemporary pharmaceutical research. Future studies are expected to further explore its mechanism of action and clinical applications, particularly in the realm of central nervous system disorders.

• 17596-79-1((S)-2-Phenyl-1-propanamine)
• 855388-71-5(2-(4-ethylphenyl)propan-1-amine)
• 55165-09-8(2-phenylpropane-1,3-diamine)
• 1213966-96-1([(1R)-1-(3-METHYLPHENYL)ETHYL]METHYLAMINE)
• 34298-25-4((R)-(+)-β-Methylphenethylamine Hydrochloride)
• 786602-39-9(2-Methyl-2-(4-methylphenyl)propan-1-amine)
• 582-22-9(beta-Methylphenethylamine)
• 5266-87-5(2-(3-methylphenyl)propan-1-amine)
• 52991-03-4(Phenethylamine, beta-methyl-, hydrochloride, (+-)-)
• 1213371-09-5(((1S)-1-[3-(METHYLETHYL)PHENYL]ETHYL)METHYLAMINE)